Managing cancer patients during the COVID-19 pandemic: An ESMO Interdisciplinary Expert Consensus.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

We established an international consortium to discuss clinical evidence and to provide expert advice on statements related to cancer management during COVID-19 pandemics. The steering committee prepared ten working packages […]

» Read more

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Recent clinical trials demonstrated safety and efficacy of neoadjuvant dabrafenib and trametinib (DT) among patients with surgically resectable clinical stage III BRAFV600E/K mutant melanoma. Although patients achieving a complete pathological […]

» Read more

An Enhanced Prognostic Score for Overall Survival of Patients with Cancer Derived from a large Real World Cohort.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

By understanding prognostic biomarkers, we gain insights into disease biology and may improve design, conduct, and data analysis of clinical trials and real world data. In this context, we used […]

» Read more

Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Transforming growth factor beta (TGFβ) is a pleiotropic cytokine that plays a key role in both physiologic and pathologic conditions, including cancer. Importantly, TGFβ can exhibit both tumor suppressive and […]

» Read more

Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

In postmenopausal, estrogen receptor-positive, HER2-negative (ER+/HER2-) early breast cancer, the risk for distant recurrence can extend beyond 5 years of adjuvant endocrine therapy. This study aims to identify genomic driver […]

» Read more

Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Patients with brain metastases (BM) from human epidermal growth factor receptor 2 (HER2)-positive breast cancer represent a difficult-to-treat population. Trastuzumab emtansine (T-DM1) has shown potential activity in this subset of […]

» Read more

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Up to 40% of patients with non-small cell lung cancer (NSCLC) and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) present with disease progression in the central nerve system […]

» Read more

Phase 1, First-in-Human Study of Futibatinib, a Highly Selective, Irreversible FGFR1-4 Inhibitor in Patients with Advanced Solid Tumors.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Futibatinib is an oral, irreversible, highly selective fibroblast growth factor receptor (FGFR)1-4 inhibitor with potent preclinical activity against tumors harboring FGFR aberrations. This first-in-human, phase 1 dose-escalation trial (NCT02052778) evaluates […]

» Read more

Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus. Results of a post-hoc analysis from the randomized phase III ACT II trial.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Concurrent chemoradiation is standard-of-care for patients with squamous cell carcinoma of the anus (SCCA). Poor compliance to chemotherapy, radiotherapy treatment interruptions and unplanned breaks may impact adversely on long-term outcomes.The […]

» Read more

Neoantigen prediction and computational perspectives towards clinical benefit: Recommendations from the ESMO Precision Medicine Working Group.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

The use of next-generation sequencing technologies has enabled the rapid identification of non-synonymous somatic mutations in cancer cells. Neoantigens are mutated peptides derived from somatic mutations not present in normal […]

» Read more

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

A common polymorphism (1245A>C) in the HSD3B1 gene is associated with increased de-novo synthesis of androgens and worse outcomes in men treated with androgen-deprivation therapy for metastatic castration-sensitive prostate cancer. […]

» Read more

Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Accumulating evidence has identified Fusobacterium as an important pathogenic gut bacterium associated with colorectal cancer (CRC). Nevertheless, only limited data exist about the role of this bacterium in locally advanced […]

» Read more

The forefront of ovarian cancer therapy: update on PARP inhibitors.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

In recurrent ovarian cancer, poly(ADP-ribose) polymerase (PARP)-inhibiting agents have transformed the treatment of platinum-sensitive disease. New data support use of PARP inhibitors earlier in the treatment algorithm.We review results from […]

» Read more

COVID-19 in patients with lung cancer.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Patients with lung cancers may have disproportionately severe COVID-19 outcomes. Understanding the patient-specific and cancer-specific features that impact severity of COVID-19 may inform optimal cancer care during this pandemic.We examined […]

» Read more

COVID-19 in patients with lung cancer.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Patients with lung cancers may have disproportionately severe COVID-19 outcomes. Understanding the patient-specific and cancer-specific features that impact severity of COVID-19 may inform optimal cancer care during this pandemic.We examined […]

» Read more

Anti-PD1 checkpoint inhibitor therapy in acral melanoma: A multicentre study of 193 Japanese patients.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Acral melanoma (AM) is an epidemiologically and molecularly distinct entity that is underrepresented in clinical trials on immunotherapy in melanoma. We aimed to analyze the real-world efficacy of anti-PD-1 antibodies […]

» Read more

The DNA Damage Response pathway as a land of therapeutic opportunities for colorectal cancer.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Colorectal cancer (CRC) represents a major cause of cancer deaths worldwide. Although significant progress has been made by molecular and immune therapeutic approaches, prognosis of advanced stage disease is still […]

» Read more

Trifluridine/Tipiracil plus Bevacizumab in Patients with Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy: the Randomized TASCO1 Study.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

We designed an open-label, non-comparative phase II study to assess the safety and efficacy of first-line treatment with trifluridine/tipiracil plus bevacizumab (TT-B) and capecitabine plus bevacizumab (C-B) in untreated patients […]

» Read more

Prognostic gene expression signature for high-grade serous ovarian cancer.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is approximately four years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated […]

» Read more

Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Brain metastases are frequent in HER2-positive breast cancer. ONT-380 (tucatinib) is a potent selective inhibitor of HER2 with intracranial activity in preclinical models.This was a phase I study of tucatinib […]

» Read more

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for extended adjuvant treatment in early-stage HER2-positive breast cancer based on the phase III ExteNET study. In that trial, in which […]

» Read more

Favourable Outcomes for High-Risk Diffuse Large B-Cell Lymphoma (IPI 3-5) Treated with Front-Line R-CODOX-M/R-IVAC Chemotherapy: Results of a Phase 2 UK NCRI Trial.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy are suboptimal but, to date, no alternative regimen has been shown to improve survival rates. This […]

» Read more

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

The predictive value of tumor mutational burden (TMB), alone or in combination with an immune gene expression profile (GEP), for response to neoadjuvant therapy in early triple negative breast cancer […]

» Read more

Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: a randomized, double-blind, phase 2 trial – REACHIN.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

There is a high unmet clinical need for treatments for advanced/metastatic biliary tract cancers (BTC) after progression on first-line chemotherapy. Regorafenib has demonstrated efficacy in some gastrointestinal tumors that progress […]

» Read more

Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Cancer diagnostics and surgery have been disrupted by the response of healthcare services to the COVID-19 pandemic. Progression of cancers during delay will impact on patient long-term survival.We generated per-day […]

» Read more

Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Cancer diagnostics and surgery have been disrupted by the response of healthcare services to the COVID-19 pandemic. Progression of cancers during delay will impact on patient long-term survival.We generated per-day […]

» Read more

Characterization of On-Target Adverse Events Caused by TRK Inhibitor Therapy.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

The TRK pathway controls appetite, balance, and pain sensitivity. While these functions are reflected in the on-target adverse effects (AEs) observed with TRK inhibition, these AEs remain under-recognized, and pain […]

» Read more

Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

The ALEX study demonstrated significantly improved progression-free survival (PFS) with alectinib versus crizotinib in treatment-naïve ALK-positive non-small-cell lung cancer (NSCLC) at the primary data cut-off (9 February 2017). We report […]

» Read more

Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

Alpelisib (α-selective PI3K inhibitor) plus fulvestrant is approved in multiple countries for men and post-menopausal women with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast […]

» Read more
1 2 3 39